NDAINJECTIONINJECTABLE
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LOXITANE IM (loxapine hydrochloride) by Teva is clinical pharmacology pharmacodynamics: pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. Approved for schizophrenia. First approved in 1979.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOXITANE IM is a loxapine hydrochloride antipsychotic administered by injection for the treatment of schizophrenia. The exact mechanism of action is not fully established, but it works through changes in subcortical inhibitory areas, producing sedation and suppression of aggressive behavior within 20-30 minutes. Loxapine is rapidly metabolized and excreted primarily within 24 hours.
LOE Approaching
As a legacy antipsychotic approaching loss of exclusivity, the brand team is likely focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics: Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such…
Indications (1)
Worked on LOXITANE IM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.